Next Article in Journal
Characterization of Equine Parvovirus in Thoroughbred Breeding Horses from Germany
Next Article in Special Issue
Generation and Characterization of a Mouse-Adapted Makona Variant of Ebola Virus
Previous Article in Journal
Equine Rhinitis A Virus Infection in Thoroughbred Racehorses—A Putative Role in Poor Performance?
Previous Article in Special Issue
Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections
Open AccessArticle

Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine

1
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway
2
Institute of Technology, University of Tartu, Tartu 50090, Estonia
3
Applied Molecular Virology Laboratory, Institut Pasteur Korea, 696 Sampyung-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Korea
4
Institute of Biomedicine, University of Turku, 20520 Turku, Finland
5
Department of Clinical Microbiology, Virology, Umeå University, 90185 Umeå, Sweden
*
Author to whom correspondence should be addressed.
Viruses 2019, 11(10), 964; https://doi.org/10.3390/v11100964
Received: 11 September 2019 / Revised: 17 October 2019 / Accepted: 18 October 2019 / Published: 18 October 2019
(This article belongs to the Special Issue Pathogenesis of Emerging Viral Infections)
Viruses are the major causes of acute and chronic infectious diseases in the world. According to the World Health Organization, there is an urgent need for better control of viral diseases. Repurposing existing antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we identified novel activities of obatoclax and emetine against herpes simplex virus type 2 (HSV-2), echovirus 1 (EV1), human metapneumovirus (HMPV) and Rift Valley fever virus (RVFV) in cell cultures. Moreover, we demonstrated novel activities of emetine against influenza A virus (FLUAV), niclosamide against HSV-2, brequinar against human immunodeficiency virus 1 (HIV-1), and homoharringtonine against EV1. Our findings may expand the spectrum of indications of these safe-in-man agents and reinforce the arsenal of available antiviral therapeutics pending the results of further in vitro and in vivo tests. View Full-Text
Keywords: virus; broad-spectrum antiviral; antiviral agent; drug target; systems biology virus; broad-spectrum antiviral; antiviral agent; drug target; systems biology
Show Figures

Figure 1

MDPI and ACS Style

Andersen, P.I.; Krpina, K.; Ianevski, A.; Shtaida, N.; Jo, E.; Yang, J.; Koit, S.; Tenson, T.; Hukkanen, V.; Anthonsen, M.W.; Bjoras, M.; Evander, M.; Windisch, M.P.; Zusinaite, E.; Kainov, D.E. Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine. Viruses 2019, 11, 964.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop